A longitudinal study of U.S. adults with metabolic dysfunction–associated steatohepatitis elucidates rates of and risk factors for progression to cirrhosis and further decompensation or death. The researchers expect these insights to help investigators improve trial protocols to better evaluate therapies for MASH.
The team evaluated a subset of adults enrolled in the multicenter, longitudinal TARGET-NASH study of patients with metabolic dysfunction–associated steatotic liver disease